Chitosan-coated nanoliposomes for the enhanced stability of walnut angiotensin-converting enzyme (ACE) inhibitory peptide

被引:12
|
作者
Cao, Shinuo [1 ]
Hao, Jing [1 ]
Wang, Yuzhen [1 ]
Zhou, Xin [1 ]
Wang, Fengjun [1 ]
机构
[1] Beijing Forestry Univ, Coll Biol Sci & Biotechnol, Dept Food Sci & Engn, Beijing Key Lab Forest Food Proc & Safety, Beijing, Peoples R China
关键词
ACE inhibitory peptide; encapsulation; nanoliposome; stability; walnut; PHYSICOCHEMICAL PROPERTIES; RELEASE BEHAVIOR; DELIVERY-SYSTEMS; CELLULAR UPTAKE; ANTIOXIDANT; ENCAPSULATION; LIPOSOMES;
D O I
10.1111/1750-3841.16562
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
This study encapsulated walnut angiotensin-converting enzyme (ACE) inhibitory peptides within nanoliposomes and then modified them with chitosan. The resulting effect of the nanoliposome loading and chitosan coating on physicochemical characteristics, stability, bioactivity, chemical structure, and morphology of the encapsulated peptides was assessed. The resulting particle size and polymer dispersity index revealed that the chitosan-coated nanoliposomes loaded with walnut ACE inhibitory peptides (WAIP) (CL-P) exhibited higher physical stability compared with the nanoliposomes loaded with WAIP (L-P). The encapsulation efficiency (EE) of CL-P increased from 73.32% to 76.13% after chitosan modification, and the EE of L-P and CL-P could be maintained by storage at 4 degrees C. In addition, the antioxidant activity and ACE inhibitory activity of the peptides were effectively protected by L-P and CL-P during storage. Fourier transform infrared spectroscopy showed that the nanoliposomes were bound in ionic form with both the peptides and chitosan. Transmission electron micrographs indicated the presence of vesicle-like carriers with a reservoir-type structure. This study highlights the potential of nanoliposomes and their modification with chitosan to increase the stability and bioactivity retention of ACE inhibitory peptides.
引用
收藏
页码:2130 / 2140
页数:11
相关论文
共 50 条
  • [31] INHIBITION OF ANGIOTENSIN-CONVERTING ENZYME (ACE) IN PLASMA AND TISSUE
    FABRIS, B
    CHEN, BZ
    PUPIC, V
    PERICH, R
    JOHNSTON, CI
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1990, 15 : S6 - S13
  • [32] The antihypertensive activity of angiotensin-converting enzyme inhibitory peptide containing in bovine lactoferrin
    Lee, NY
    Cheng, JT
    Enomoto, T
    Nakamura, I
    CHINESE JOURNAL OF PHYSIOLOGY, 2006, 49 (02): : 67 - 73
  • [33] MULTIPLE FORMS OF ANGIOTENSIN-CONVERTING ENZYME (ACE) CDNA
    BERNSTEIN, K
    MARTIN, B
    LABORATORY INVESTIGATION, 1989, 60 (01) : A9 - A9
  • [34] SEQUENCE OF THE PROMOTER REGION OF ANGIOTENSIN-CONVERTING ENZYME (ACE)
    SHAI, SY
    LANGFORD, K
    BERNSTEIN, K
    KIDNEY INTERNATIONAL, 1990, 37 (01) : 359 - 359
  • [35] Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis
    Tomita, H
    Ina, Y
    Sugiura, Y
    Sato, S
    Kawaguchi, H
    Morishita, M
    Yamamoto, M
    Ueda, R
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 156 (01) : 255 - 259
  • [36] MULTIPLE FORMS OF ANGIOTENSIN-CONVERTING ENZYME (ACE) CDNA
    BERNSTEIN, KE
    MARTIN, BM
    KIDNEY INTERNATIONAL, 1989, 35 (01) : 298 - 298
  • [37] Angiotensin-converting enzyme (ACE) gene polymorphism in preeclampsia
    Machado, MW
    Cabral, S
    Costa, BEP
    Scheibe, R
    de Figueiredo, CEP
    HYPERTENSION, 2001, 37 (03) : 1023 - 1023
  • [38] Serum angiotensin-converting enzyme (ACE) is altered at altitude
    Kamikomaki, N
    Nishioka, O
    HIGH ALTITUDE MEDICINE & BIOLOGY, 2004, 5 (04) : 465 - 466
  • [39] ANGIOTENSIN-CONVERTING ENZYME (ACE) IN PATIENTS WITH TEMPORAL ARTERITIS
    RADDA, TM
    KUZMITS, R
    WIENER KLINISCHE WOCHENSCHRIFT, 1985, 97 (21) : 801 - 805
  • [40] ANGIOTENSIN-CONVERTING ENZYME (ACE) POLYMORPHISM IN PATIENTS WITH TERMINAL
    SCHMIDT, A
    KIENER, H
    HAAS, M
    GRANINGER, W
    ARIAS, E
    MAYER, G
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03): : 652 - 652